Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Exact Sciences (NASDAQ: EXAS) revealed clinical validation data for its Oncodetect MRD test at ASCO GI 2025. The Alpha-CORRECT study demonstrated the test's effectiveness in detecting molecular residual disease in colorectal cancer patients, achieving 78% sensitivity post-surgery and 91% during surveillance, with specificities of 80% and 94% respectively.
The Beta-CORRECT study confirmed Oncodetect's prognostic value across stages II, III, and IV colon cancer and rectal cancer. The company plans to launch Oncodetect in Q2 2025 with Medicare coverage. Exact Sciences has established partnerships with NSABP and Flatiron Health to generate additional clinical evidence across multiple solid tumor types, including the CORRECT-I, CORRECT-II, and EXActDNA-003 studies.
Exact Sciences (NASDAQ: EXAS) will present 11 abstracts at the ASCO GI Symposium in January 2025, showcasing significant advances in cancer screening and diagnostics. The company's Oncodetect™ molecular residual disease (MRD) test demonstrated strong performance in Stage III colon cancer patients, with 78% sensitivity post-surgery and 91% during surveillance, along with specificities of 80% and 94% respectively.
The data reveals high adherence rates for the Cologuard® test across different demographic groups: African Americans (62%), Hispanic population (63%), Asian population (69%), and 45-49-year-olds (65%). These rates significantly exceed the generally accepted FIT adherence of 42%. New modeling data indicates that screening with triennial Cologuard results in fewer colorectal cancer cases, lower treatment costs, and higher life years gained compared to blood-based tests at perfect adherence.
Exact Sciences (NASDAQ: EXAS) has announced preliminary Q4 2024 results, expecting total revenue of $713 million, up 10% year-over-year. The company's Screening segment revenue reached $553 million (+14%), while Precision Oncology revenue was $161 million (+0.4%).
For full-year 2024, Exact Sciences anticipates total revenue of $2.76 billion, representing a 10% increase from 2023. The company's Screening revenue grew 13% to $2.104 billion, and Precision Oncology revenue increased 4% to $655 million.
Looking ahead to 2025, the company plans to launch three new cancer tests: Cologuard Plus for colorectal cancer screening, Oncodetect for molecular residual disease, and Cancerguard for multi-cancer screening.
Exact Sciences (Nasdaq: EXAS), a leading cancer screening and diagnostic tests provider, has announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation followed by a Q&A session on Monday, January 13, 2025, at 1:30 p.m. ET.
Investors and interested parties can access the webcast through the investor relations section of Exact Sciences' website at www.exactsciences.com.
Exact Sciences (Nasdaq: EXAS), a cancer screening and diagnostic tests provider, has announced its management's participation in two upcoming investor conferences in Miami. The company will hold fireside chats at the Citi Global Healthcare Conference on December 3, 2024, at 8:45 a.m. ET, and at the Evercore HealthCONx Conference on December 4, 2024, at 7:30 a.m. ET. Investors can access the webcasts through the investor relations section of Exact Sciences' website.
Exact Sciences (NASDAQ: EXAS) will present 10 abstracts at the 2024 San Antonio Breast Cancer Symposium, showcasing their Precision Oncology portfolio. The presentations focus on the Oncotype DX Breast Recurrence Score® test, highlighting its effectiveness in guiding chemotherapy decisions and managing treatment costs.
New research from Japan demonstrates the test's cost-effectiveness, while other studies reveal that African American women typically show higher Recurrence Score® results compared to non-Hispanic White women, though with similar survival outcomes. The company aims to improve breast cancer care through personalized treatment planning and innovative solutions across all stages of cancer care.
Exact Sciences (NASDAQ: EXAS) presented three abstracts showcasing advancements in multi-cancer early detection (MCED) testing at the AACR Special Conference. A new study demonstrated that their multi-biomarker class approach improved cancer detection sensitivity, showing a 28% increase for stage I cancers and 12.5% for early-stage cancers at 98.5% specificity. New modeling data suggests that adding MCED testing to standard screening could reduce stage IV cancer incidence by 42% and cancer mortality by 17% over 10 years. Analysis from the DETECT-A study indicated MCED testing complements existing lung cancer screening without affecting adherence to standard care.
Exact Sciences reported Q3 2024 total revenue of $709 million, up 13% year-over-year, with Screening revenue of $545 million (+15%) and Precision Oncology revenue of $164 million (+5%). Despite recording a net loss of $38 million, the company achieved an adjusted EBITDA of $99 million with a 14% margin, representing a 500 basis point improvement. Operating cash flow reached $139 million with free cash flow of $113 million. Notable developments include FDA approval for Cologuard Plus™ test and promising results from their blood-based colorectal cancer screening test. However, the company revised down its full-year 2024 guidance for both revenue and adjusted EBITDA.
Exact Sciences (Nasdaq: EXAS), a leader in cancer screening and diagnostic tests, has announced its upcoming participation in the Jefferies London Healthcare Conference. The company will host a fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET in London. Investors can access the webcast through the investor relations section of Exact Sciences' website.
Exact Sciences (NASDAQ: EXAS) will present modeling data at the American College of Gastroenterology Annual Meeting showcasing the Cologuard Plus™ test's effectiveness in colorectal cancer screening. The modeling data demonstrates that Cologuard Plus delivers the highest life-years gained with fewer colonoscopies among noninvasive screening strategies. The company will also present seven abstracts focusing on improving screening adherence rates, particularly in underserved populations. Studies show high adherence rates of 71.2% across insured individuals, with Spanish language support achieving 76.7% adherence. Implementation of reported strategies could potentially reduce the CRC screening gap by up to 10%.